Rallybio CORP

Rallybio Corporation announced a merger with Avenzo Therapeutics, Inc., a clinical-stage oncology company, and a concurrent $215 million private placement financing.

Rallybio Corporation announced the termination of its merger agreement with Candid Therapeutics, Inc., and concurrently entered into a new agreement with UCB S.A., securing a $50 million termination fee.

Rallybio Corporation announced the immediate departure of Chief Medical Officer Steven Ryder, M.D., with severance and equity terms tied to the pending merger with Candid Therapeutics.

Rallybio Corporation will merge with clinical-stage Candid Therapeutics, Inc., with Candid's equityholders taking a majority stake and a concurrent $505.5 million financing to fund operations through 2030.

Rallybio Corporation will implement a 1-for-8 reverse stock split of its common stock effective February 6, 2026, following stockholder approval.

Rallybio Corporation announced a net income of $16.0 million for the third quarter of 2025 and extended its cash runway through 2027.

Rallybio Corporation achieved net income in Q3 2025 driven by a strategic joint venture sale, extending its cash runway through 2027 while advancing its lead rare disease programs.

Rallybio Corporation significantly reduced its net loss and operating expenses in Q2 2025, extending its cash runway into mid-2027, despite discontinuing its RLYB212 program.

Rallybio announces Q1 2025 financial results, highlighting progress in RLYB116 development and pipeline prioritization.

Rallybio Corporation released its third quarter 2024 financial results, highlighting progress in its clinical programs and strategic collaborations.

Rallybio Corporation announced its second quarter 2024 financial results, highlighting progress in its clinical programs and a new collaboration with Johnson & Johnson.

Rallybio Corporation announced its first quarter 2024 financial results, highlighting a strategic shift to prioritize the development of RLYB212 and a workforce reduction.

Rallybio Corporation announces a definitive merger agreement with Candid Therapeutics, shifting its strategic focus to T-cell engager therapeutics and monetizing legacy assets through Contingent Value Rights.

Rallybio's 10-K filing summarizes the company's financial performance for 2024 and provides updates on its clinical development programs, including RLYB212 and RLYB116.

Rallybio's 2023 annual report highlights the company's progress in clinical development, particularly for RLYB212 and RLYB116, while also outlining strategic shifts and financial results.

Rallybio Corporation announced a definitive agreement to acquire Avenzo Therapeutics, Inc., a clinical-stage oncology company, for an undisclosed sum, alongside a concurrent $215 million private placement financing.

ADAR1 Capital Management, LLC reported the acquisition of 16,209 shares of Rallybio Corp common stock across multiple transactions.

ADAR1 Capital Management, LLC reported the acquisition of 79,559 shares of Rallybio Corp common stock between May 13 and May 15, 2026.

ADAR1 Capital Management, LLC and Daniel Schneeberger have increased their beneficial ownership in Rallybio Corp through recent open market purchases.

ADAR1 Capital Management and Daniel Schneeberger acquired 155,905 shares of Rallybio Corp, signaling strong institutional confidence.

Rallybio Corporation will acquire clinical-stage Candid Therapeutics in a merger, backed by over $505 million in new financing, to advance a T-cell engager pipeline for autoimmune diseases.

Rallybio Corporation seeks stockholder approval for a reverse stock split to maintain its Nasdaq listing and enhance stock marketability.

Rallybio Corporation announces its 2025 Annual Meeting of Stockholders to be held virtually on May 13, 2025, with key proposals including the election of directors and ratification of the company's independent accounting firm.

Rallybio Corporation announces its 2024 Annual Meeting of Stockholders to be held virtually on May 15, 2024, to elect directors and ratify the selection of its independent accounting firm.

Venture capital firm 5AM Ventures has disclosed the sale of approximately 291,788 shares of Rallybio Corp common stock.

5AM Ventures and its affiliates have filed an Amendment No. 2 to their Schedule 13D, reporting a reduction in their beneficial ownership of Rallybio Corp common stock following recent open market sales.

ADAR1 Capital Management and Daniel Schneeberger have reported a 17.5% beneficial ownership stake in Rallybio Corporation.

Viking Global Investors LP filed an amendment to its Schedule 13G, reporting a 9.99% beneficial ownership stake in Rallybio Corporation.

Nantahala Capital Management, LLC and its principals have reported a 5.68% beneficial ownership stake in Rallybio Corporation.

Cormorant Asset Management, LP and Bihua Chen have reported beneficial ownership of 400,000 shares, representing 7.56% of Rallybio Corp's common stock.

Balyasny Asset Management L.P. and affiliated entities have reported beneficial ownership of 7.12% of Rallybio Corp's common stock as of March 31, 2026.

Laurion Capital Management LP, along with individuals Benjamin Alexander Smith and Janaka Sheehan Maduraperuma, has reported beneficial ownership of 5.72% of Rallybio Corp's common stock as of March 31, 2026.